Background: Rural/remote blood collection can cause delays in processing, reducing PBMC number, viability, cell composition and function. To mitigate these impacts, blood was stored at 4 °C prior to processing. Viable cell number, viability, immune phenotype, and Interferon-γ (IFN-γ) release were measured. Furthermore, the lowest protective volume of cryopreservation media and cell concentration was investigated. Methods: Blood from 10 individuals was stored for up to 10 days. Flow cytometry and IFN-γ ELISPOT were used to measure immune phenotype and function on thawed PBMC. Additionally, PBMC were cryopreserved in volumes ranging from 500 µL to 25 µL and concentration from 10 × 106 cells/mL to 1.67 × 106 cells/mL. Results: PBMC viability and viable cell number significantly reduced over time compared with samples processed immediately, except when stored for 24 h at RT. Monocytes and NK cells significantly reduced over time regardless of storage temperature. Samples with >24 h of RT storage had an increased proportion in Low-Density Neutrophils and T cells compared with samples stored at 4 °C. IFN-γ release was reduced after 24 h of storage, however not in samples stored at 4 °C for >24 h. The lowest protective volume identified was 150 µL with the lowest density of 6.67 × 106 cells/mL. Conclusion: A sample delay of 24 h at RT does not impact the viability and total viable cell numbers. When long-term delays exist (>4 d) total viable cell number and cell viability losses are reduced in samples stored at 4 °C. Immune phenotype and function are slightly altered after 24 h of storage, further impacts of storage are reduced in samples stored at 4 °C.
Aims/hypothesis: Children with early-stage (pre-symptomatic) type 1 diabetes are currently identified primarily via research-based screening programmes in Australia. Once identified, families live with the knowledge that their child has an increased chance of developing symptomatic, lifelong, insulin-requiring type 1 diabetes but have no specific clinical pathway available to them in Western Australia (WA) for accessing tailored support or education. This project aimed to co-design a new clinical pathway to address this unmet need. Methods: Experience-based co-design (EBCD) methodology was applied, comprising three phases undertaken consecutively over 12 months. Recruitment for each phase was via open invitation with voluntary participation. Phases 1 and 2 involved facilitated community conversations and focus groups conducted separately for type 1 diabetes community members and healthcare professionals (HCPs). Data from these phases were analysed using deductive and inductive content analysis to identify key categories of information and a prototype clinical pathway was developed incorporating these. For phase 3, a combined workshop was held with all stakeholders to obtain feedback on the prototype, and refine it accordingly. Results: In phase 1, 16 community members (people living with type 1 diabetes, families whose child or children had been screened for type 1 diabetes) and 36 HCPs (doctors, nurse educators, social workers, dietitians, a mental health nurse and administrative staff from Perth Children’s Hospital) participated in separate community conversations. The following three key categories were identified: (1) the need for education; (2) the need for support and strategies for managing uncertainty; and (3) the need for information on disease-modifying therapies and access to clinical trials. In phase 2, seven community members and 11 HCPs participated in separate focus groups. The following key priorities were identified: (1) the need for access to HCPs skilled in supporting patients to manage uncertainty; (2) the need for flexibility in delivery modes (telehealth/in-person); (3) the need for early referral to relevant clinical trials; and (4) the need for reliable and up-to-date resources. In phase 3, three community members and three HCPs attended a combined workshop to provide feedback on a prototype clinical pathway and their feedback was incorporated into a final version. Conclusions/interpretation: Application of EBCD methodology enabled the development of a new clinical pathway tailored to the needs of WA families with a child living with early-stage type 1 diabetes. Graphical
19 August 2021 in The Journal of Clinical Endocrinology & Metabolism
Context Dietary fat and protein impact postprandial hyperglycaemia in people with type 1 diabetes, but the underlying mechanisms are poorly understood. Glucoregulatory hormones are also known to modulate gastric emptying and may contribute to this effect. Objective Investigate the effects of fat and protein on glucagon like peptide (GLP-1), glucagon-dependent insulinotropic polypeptide (GIP) and glucagon secretion. Design Two cross-over euglycaemic insulin clamp clinical trials. Setting Two Australian paediatric diabetes centres. Participants 12-21years (n=21) with type 1 diabetes for ≥1year. Intervention(s) Participants consumed a low protein (LP) or high protein (HP) meal in Study 1, and low protein/low fat (LPLF) or high protein/high fat (HPHF) meal in Study 2, all containing 30g carbohydrate. An insulin clamp was used to maintain postprandial euglycaemia and plasma glucoregulatory hormones were measured every 30 minutes for 5-hours. Data from both cohorts (n=11,10) were analysed separately. Main Outcome Area under the curve of GLP-1, GIP and glucagon. Results Meals low in fat and protein had minimal effect on GLP-1, while there was sustained elevation after the HP (80.3±16.8pmol/L) vs LP (56.9±18.6), P=0.016, and HPHF (103.0±26.9) vs LPLF (69.5±31.9) meals, P=0.002. The prompt rise in GIP after all meals was greater after the HP (190.2±35.7pmol/L) vs LP (152.3±23.3), P=0.003, and HPHF (258.6±31.0) vs LPLF (151.7±29.4), P<0.001. A rise in glucagon was also seen in response to protein, HP (292.5±88.1pg/mL) vs LP (182.8±48.5), P=0.010. Conclusions The impact of fat and protein on postprandial glucose excursions may be mediated by the differential secretion of glucoregulatory hormones. Further studies to better understand these mechanisms may lead to improved personalised postprandial glucose management.
The optimal time to bolus insulin for meals is challenging for children and adolescents with type 1 diabetes (T1D). Current guidelines to control glucose excursions do not account for individual differences in glycaemic responses to meals. This study aimed to examine the within- and between-person variability in time to peak (TTP) glycaemic responses after consuming meals under controlled and free-living conditions. Participants aged 8–15 years with T1D ≥ 1 year and using a continuous glucose monitor (CGM) were recruited. Participants consumed a standardised breakfast for six controlled days and maintained their usual daily routine for 14 free-living days. CGM traces were collected after eating. Linear mixed models were used to identify within- and between-person variability in the TTP after each of the controlled breakfasts, free-living breakfasts (FLB), and free-living dinners (FLD) conditions. Thirty participants completed the study (16 females; mean age and standard deviation (SD) 10.5 (1.9)). The TTP variability was greater within a person than the variability between people for all three meal types (between-person vs. within-person SD; controlled breakfast 18.5 vs. 38.9 min; FLB 14.1 vs. 49.6 min; FLD 5.7 vs. 64.5 min). For the first time, the study showed that within-person variability in TTP glycaemic responses is even greater than between-person variability.
Aim: To explore the lived experiences of parents of children at risk of type 1 diabetes (T1D) undergoing repeated blinded continuous glucose monitoring (CGM). Method: Since 2021, children with persistent islet autoimmunity in the Environmental Determinants of Islet Autoimmunity (ENDIA) study have been invited to participate in a sub‐study involving blinded Dexcom G6 CGM. Parents with children undergoing repeated CGM participated in a semi‐structured audio call interview. Open‐ended questions captured their experiences of their child's repeated blinded CGM. Data were analysed using inductive thematic analysis. Results: Nineteen parents (18 mothers, 1 father) of children with a mean (SD) age of 7.5 (1.3) years, who had undergone a mean 5.5 (3.2) CGM assessments, were interviewed for a mean duration of 21.3 (8.0) minutes. Three main themes were identified: Challenges of CGM wear : All parents identified at least one difficult experience (e.g. pain with sensor insertion, anxiety of data loss) during CGM assessments Content and timing of feedback of CGM assessment findings : Parents described a range of experiences related to receiving feedback from health care professionals and their child's stage of T1D. Preparation for diagnosis of clinical (Stage 3) T1D and initiation of insulin treatment : Parents described feeling empowered by knowing their child's risk, allowing them to feel more prepared for progression to Stage 3 T1D. Conclusion: Despite the challenges parents face while their child undergoes CGM assessments, they reported repeated blinded CGM as an acceptable form of monitoring that provided valuable knowledge regarding their child's risk of stage 3 type 1 diabetes.